JW MARRIOTT

CHICAGO, ILLINOIS

*EARN UP TO 11.25 CME

May 5, 2023 – May 6, 2023

In-Person
swoosh
swoosh

ACCREDITATION

TARGET AUDIENCE

This activity is intended for Dermatologists, Dermatology Residents/Fellows, Physician Assistants, Nurse Practitioners, and other health professionals interested in treating patients with dermatologic diseases.

 

LEARNING OBJECTIVES
After completing this activity, the participant should be better able to: 

[LIST] [ITEM]Recognize the epidemiology and prevalence and etiopathogenesis of pigmentary disorders across all skin phototypes. [ITEM]Discuss the clinical features of pigmentary disorders that contribute to the burden of disease, psychosocial implications, and diminished quality of life. [ITEM]Review best practices for achieving a timely and accurate diagnosis of pigmentary disorders to initiate appropriate treatment.   [ITEM]Evaluate available clinical evidence on the mechanism of action, efficacy, safety, and tolerability of available treatment modalities for pigmentary disorders. [ITEM] Discuss new and emerging treatments in the context of disease pathogenesis, as well as recent clinical trial results. [ITEM]Summarize features and benefits of cosmeceutical and photoprotection product use as part of a comprehensive treatment care regimen for dyspigmentation. [ITEM]Formulate multimodality treatment plans for pigmentary disorders that reflect current evidence-based recommendations and take patient-specific factors into consideration. [ITEM]Describe the indications for the use of lasers and phototherapy devices in patients with pigmentary disorders across skin phototypes, and how to mitigate the risks of complications with laser use. [ITEM]Review mental health screening and patient education strategies to encourage adherence to therapeutic regimens, prevent recurrence, and improve quality of life. [/LIST]

CME Symposium: Diving Beneath the Surface in Vitiligo Management: The Role of New Targeted Therapies

  • Recognize the epidemiology and prevalence and etiopathogenesis of pigmentary disorders across all skin phototypes.
  • Discuss the clinical features of pigmentary disorders that contribute to the burden of disease and diminished quality of life.
  • Review best practices for achieving a timely and accurate diagnosis of pigmentary disorders in patients of all skin phototypes to initiate appropriate treatment.
  • Evaluate available clinical evidence on the mechanism of action, efficacy, safety, and tolerability of available and emerging treatment modalities for pigmentary disorders.
  • Identify multimodality treatment plans for pigmentary disorders that reflect current evidence-based recommendations and take patient-specific factors into consideration.
  • Describe the indications for the use of lasers and phototherapy devices in patients with pigmentary disorders across skin phototypes, and how to mitigate the risks of complications with laser use.

 

 

JOINT ACCREDITATION STATEMENT


 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [bold]Physician Continuing Medical Education[/bold] The Postgraduate Institute for Medicine designates this live activity for a maximum of 11.25 [italic]AMA PRA Category 1 Credits™. [/italic]Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

DISCLOSURES OF CONFLICTS OF INTEREST
 

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.